Cargando…

Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease

Chronic graft-versus-host disease (cGVHD) remains a frequent cause of non-relapse morbidity and mortality after allogeneic hematopoietic stem cell transplantation. In our single center trials of low-dose interleukin-2 (LD IL-2), the immunomodulatory properties of regulatory T cells (Tregs) have been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donato, Veronica, Kim, Haesook T., Stowe, Peter, Reynolds, Carol G., Ritz, Jerome, Koreth, John, Whangbo, Jennifer S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515381/ https://www.ncbi.nlm.nih.gov/pubmed/36189229 http://dx.doi.org/10.3389/fimmu.2022.954966

Ejemplares similares

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease
por: Kim, Haesook T., et al.
Publicado: (2022)

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease
por: Whangbo, Jennifer S., et al.
Publicado: (2022)

Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease
por: Wobma, Holly, et al.
Publicado: (2023)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

Translational and clinical advances in acute graft-versus-host disease
por: Gooptu, Mahasweta, et al.
Publicado: (2020)

ANALYSIS OF GRAFT-VERSUS-HOST DISEASE IN SYRIAN HAMSTERS : IV. THE REFRACTORY STATE AND IMMUNOLOGIC COMPETENCE
por: Streilein, J. Wayne
Publicado: (1972)

Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation
por: Kekre, Natasha, et al.
Publicado: (2017)

Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease
por: Shen, Meng-Zhu, et al.
Publicado: (2021)

Editorial: Regulatory T cells in graft versus host disease
por: Rodríguez-Gil, Alfonso, et al.
Publicado: (2023)

Steroid-Refractory Gut Graft-Versus-Host Disease: What We Have Learned From Basic Immunology and Experimental Mouse Model
por: Song, Qingxiao, et al.
Publicado: (2022)

Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease
por: Chen, George L., et al.
Publicado: (2022)

Durable discontinuation of systemic therapy for chronic graft-versus-host disease: myth or reality?
por: Pavletic, Steven Z., et al.
Publicado: (2022)

Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation
por: Rambaldi, Benedetta, et al.
Publicado: (2022)

Clinical Metabolomics Identifies Blood Serum Branched Chain Amino Acids as Potential Predictive Biomarkers for Chronic Graft vs. Host Disease
por: Alborghetti, Marcos Rodrigo, et al.
Publicado: (2019)

Murine Models of Steroid Refractory Graft-versus-Host Disease
por: Toubai, Tomomi, et al.
Publicado: (2018)

Immunological heterogeneity informs estimation of the durability of vaccine protection
por: Domenech de Cellès, Matthieu, et al.
Publicado: (2022)

Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome
por: Brown, Jennifer R., et al.
Publicado: (2012)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

The Graz Liver Allocation Strategy—Impact of Extended Criteria Grafts on Outcome Considering Immunological Aspects
por: Kahn, Judith, et al.
Publicado: (2020)

Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease
por: Abedin, Sameem, et al.
Publicado: (2020)

Synergistic targeting of immunologic pathways to empower durable tolerance therapies
por: Nepom, Gerald T.
Publicado: (2022)

ENDURAGen graft durability in α-Gal disease
por: Ruland, Kelly L., et al.
Publicado: (2022)

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse
por: Shapiro, Roman M., et al.
Publicado: (2023)

Extended-schedule dose-dense temozolomide in refractory gliomas
por: Berrocal, A., et al.
Publicado: (2009)

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells
por: Maurer, Katie, et al.
Publicado: (2023)

Therapy with mycophenolate mofetil for refractory acute and chronic graft-versus-host disease
por: Furlong, Terry, et al.
Publicado: (2009)

Intramesenteric Steroid Treatment for Steroid- Refractory Gastrointestinal Graft Versus Host Disease
por: Bilgin, Aynur Uğur, et al.
Publicado: (2012)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

Treatment and unmet needs in steroid-refractory acute graft-versus-host disease
por: Malard, Florent, et al.
Publicado: (2020)

Fecal microbiota transplantation for steroid-refractory gastrointestinal graft-versus-host disease
por: Kim, Hyun Min, et al.
Publicado: (2023)

Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma
por: Khoury, Sami, et al.
Publicado: (2021)

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results
por: Koreth, John, et al.
Publicado: (2018)

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
por: Sarmiento Maldonado, Mauricio, et al.
Publicado: (2017)

Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease
por: Gunes, Gursel, et al.
Publicado: (2015)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Steroid-refractory chronic graft-versus-host disease: treatment options and patient management
por: Wolff, Daniel, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation
por: Kim, Haesook T., et al.
Publicado: (2021)

Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation
por: Lamarthée, Baptiste, et al.
Publicado: (2016)

Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease
por: Le, Hongnga T., et al.
Publicado: (2020)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vf395plsn47u3demk3919q3tq4